Glenview, IL2 Active Studies

Benign Prostatic Hyperplasia Clinical Trials in Glenview, IL

Find 2 actively recruiting benign prostatic hyperplasia clinical trials in Glenview, IL. Connect with local research sites and explore new treatment options.

2
Active Trials
2
Sponsors
370
Enrolling

Recruiting Benign Prostatic Hyperplasia Studies in Glenview

About Benign Prostatic Hyperplasia Clinical Trials in Glenview

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland that can cause urinary symptoms in men. It becomes increasingly common with age, affecting most men over 50. Treatment includes alpha-blockers, 5-alpha reductase inhibitors, and minimally invasive procedures.

There are currently 2 benign prostatic hyperplasia clinical trials recruiting participants in Glenview, IL. These studies are seeking a combined 370 participants. Research is being sponsored by Northwestern University, Endeavor Health. Clinical trial participation is free and participants receive study-related medical care at no cost.

Benign Prostatic Hyperplasia Clinical Trials in Glenview — FAQ

Are there benign prostatic hyperplasia clinical trials in Glenview?

Yes, there are 2 benign prostatic hyperplasia clinical trials currently recruiting in Glenview, IL. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Glenview?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Glenview research site will contact you about next steps.

Are clinical trials in Glenview free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Glenview studies also compensate for your time and travel.

What benign prostatic hyperplasia treatments are being tested?

The 2 active trials in Glenview are testing new therapies including novel drugs, biologics, and treatment approaches for benign prostatic hyperplasia.

Data updated July 13, 2026 from ClinicalTrials.gov